natgillin/translations-raw huggingface dataset:
Skin and subcutaneous tissue disorders Skin disorder 
Bolezni kože in podkožja kožne spremembe izpuščaj Λ °
To reconstitute lyophilised interferon beta-1b for injection, connect the vial adapter with the attached needle on the vial. 
Rekonstitucija Za rekonstitucijo liofiliziranega interferona beta-1b za injiciranje je treba v vialo z zdravilom
2nd dosage step (0.5 ml) for treatment days 7, 9, 11 
2. korak odmerjanja (0,5 ml) za 7., 9. in 11. dan zdravljenja Tridelno pakiranje 3
Bayer AS 
Bayer Oy
The titration period may be adjusted, if any significant adverse reaction occurs. 
Če se pojavijo resni neželeni učinki, se lahko obdobje titriranja prilagodi.
Patients and investigators remained blinded to the initial treatment allocation. 
Bolniki in preskuševalci niso vedeli, v katero skupino je bil bolnik na začetku randomiziran.
SIA Bayer 
Latvija SIA Bayer
It contains specially marked syringes with 0.50 ml marking. 
Vsebuje brizge z oznako 0,5 ml.
Part of a multipack containing 15 single packs. 
Del škatle z več pakiranji, ki vsebuje 15 posameznih pakiranj.
Nephrotic Syndrome 
hemolitičnouremičnim sindromom3
How to store Betaferon 
Shranjevanje zdravila Betaferon
Immediate Betaferon 250 mcg n=292 
takojšnje zdravljenje z zdravilom Betaferon mikrogramov n = 292
i.e. the following terms: injection site haemorrhage, injection site hypersensitivity, injection site inflammation, injection site mass, injection site necrosis, injection site pain, injection site reaction, injection site oedema, and injection site atrophy & “Flu-like symptom complex” denotes flu syndrome and/or a combination of at least two AEs from fever, chills, myalgia, malaise, sweating. 
Λ pomembno povezano z zdravljenjem z zdravilom Betaferon pri bolnikih s prvim kliničnim dogodkom, ki kaže na MS, p < 0,05 * statistično značilno povezano z uporabo zdravila Betaferon pri RR-MS, p < 0,05 ° statistično značilno povezano z uporabo zdravila Betaferon pri SP-MS, p < 0,05 § reakcije na mestu injiciranja (različne vrste) sestavljajo vsi neželeni učinki na mestu injiciranja, kot so krvavitev na mestu injiciranja, preobčutljivost na mestu injiciranja, vnetje na mestu injiciranja, hipertrofija na mestu injiciranja, nekroza na mestu injiciranja, bolečina na mestu injiciranja, reakcija na mestu injiciranja, edem na mestu injiciranja in atrofija na mestu injiciranja & "kompleks gripi podobnih simptomov" pomeni sindrom gripe in/ali kombinacijo vsaj dveh izmed naslednjih neželenih učinkov: zvišana telesna temperatura, mrzlica, mialgija, splošno slabo počutje, znojenje.
- the number of red cells in the blood may fall (anaemia) - the thyroid gland does not work properly (too little hormone is produced) (hypothyroidism) - weight increase or decrease - confusion - abnormally rapid heartbeat (tachycardia) - a reddish yellow pigment (bilirubin), which is produced by your liver, may rise (this will show up in blood tests) - swollen and usually itchy patches of skin or mucous membranes (urticaria) - itching (pruritus) - loss of scalp hair (alopecia) - menstrual disorders (menorrhagia) 
- nenormalno hiter srčni utrip (tahikardija) - povečajo se lahko vrednosti rdečkasto rumenega barvila (bilirubin), ki nastaja v jetrih (to pokažejo krvne preiskave) - otekli in običajno srbeči predeli kože ali sluznice (urtikarija)
Menorrhagia 
Betaferon
Hepatic injury (including hepatitis), Hepatic failure2 
- nepravilno delovanje jeter (poškodba jeter, (vključno s hepatitisom), odpoved jeter),
14 - After drawing up the solution turn the syringe assembly so that the needle is pointing up. 
14 - Po izvleku raztopine sklop brizge obrnite tako, da je igla obrnjena navzgor.
Abdominal pain ° 
čustvena labilnost
Talk to your doctor before you start using Betaferon: 
Preiskave je treba opraviti preden začnete uporabljati zdravilo
It is a good idea to know where you plan to inject before you prepare your syringe. 
Svetujemo, da se za mesto injiciranja odločite vnaprej, preden pripravite brizgo.
Periodic monitoring of early signs or symptoms, e.g. oedema, proteinuria and impaired renal function is recommended, especially in patients at higher risk of renal disease. 
Predvsem pri bolnikih z večjim tveganjem za ledvično bolezen se priporoča periodično spremljanje glede zgodnjih znakov ali simptomov, kot so npr. edem, proteinurija in okvarjeno delovanje ledvic.
Betaferon must be used with caution, and your doctor will monitor you for worsening of your heart condition, particularly during the start of treatment. 
Zdravnik bo spremljal morebitno poslabšanje bolezni srca, še zlasti na začetku zdravljenja.
General disorders and administration site conditions Injection site reaction (various kinds) Λ * ° § 
Splošne težave in spremembe na mestu aplikacije reakcija na mestu injiciranja (različne vrste) Λ * ° § nekroza na mestu injiciranja * ° gripi podobni simptomi & Λ * ° zvišana telesna temperatura Λ * °
► Rare (may affect up to 1 in 1,000 users): 
- sprememba barve kože ► redki (pojavijo se lahko pri največ 1 od 1.000 bolnikov)
- Clean the injection site with an alcohol wipe and let it air-dry. 
- Z alkoholno blazinico očistite mesto injiciranja.
NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Solvent for reconstitution of Betaferon 
IME ZDRAVILA IN POT UPORABE
Solvent (sodium chloride solution 5.4 mg/ml (0.54% w/v)): Sodium chloride 
Vehikel (raztopina natrijevega klorida 5,4 mg/ml (0,54 % m/v)) natrijev klorid voda za injekcije
What you need to know before you use Betaferon 
Kaj morate vedeti, preden boste uporabili zdravilo Betaferon Ne uporabljajte zdravila Betaferon
Blood and lymphatic system disorders 
Bolezni krvi in limfatičnega sistema anemija trombocitopenija trombotična mikroangiopatija,
It has been demonstrated in vitro that Betaferon cross-reacts with natural interferon beta. 
In vitro je dokazano, da zdravilo Betaferon navzkrižno reagira z naravnim interferonom beta, vendar tega niso preučevali in vivo; klinični pomen tega izsledka ni jasen.
Clinical efficacy and safety 
Klinična učinkovitost in varnost Recidivno-remitentna multipla skleroza
Part of a pack containing 14 single packs in a 3-month pack of 3x14 single packs. 
Del pakiranja, ki vsebuje 14 posameznih pakiranj v 3-mesečnem pakiranju s 3 x 14 posameznimi pakiranji.
After reconstitution, each millilitre contains 250 microgram (8.0 million IU) interferon beta-1b. 
Po rekonstituciji vsebuje vsak mililiter 250 mikrogramov (8,0 milijonov i.e.) interferona beta-1b.
− rotate the injection sites with each injection (see Annex ‘Self-injection procedure', Part II, in the second part of this leaflet). 
- uporabljajte sterilno (aseptično) tehniko injiciranja, - pri vsakem odmerku menjavajte mesto injiciranja (glejte Dodatek: Postopek samoinjiciranja, del
1.0 ml * The titration period may be adjusted, if any significant adverse reaction occurs. 
* Če se pojavijo resni neželeni učinki, se lahko obdobje titriranja prilagodi.
- painful joints (arthralgia) 
kratka sapa (dispneja)
40% versus delayed Betaferon 
40 % v primerjavi z odloženim zdravljenjem z zdravilom Betaferon
The mechanisms by which interferon beta-1b exerts its actions in multiple sclerosis are not clearly understood. 
Mehanizmi, prek katerih deluje pri multipli sklerozi, niso povsem pojasnjeni.
immediate use recommended. 
- Navodilo shranite.
− titration pack for the first 12 injections comprising 4 triple packs, each containing 3 vials with powder, 3 pre-filled syringes with solvent, 3 vial adapters with needle, 6 alcohol wipes 
vialo s praškom, 1 napolnjeno injekcijsko brizgo z vehiklom, 1 adapter za vialo z iglo, 2 alkoholni blazinici ali - set za titriranje (za prvih 12 injekcij), ki vsebuje štiri tridelna pakiranja; vsako tridelno pakiranje vsebuje 3 viale s praškom, 3 napolnjene injekcijske brizge z vehiklom, 3 adapterje za viale z iglami, 6 alkoholnih blazinic.
Betaferon contains mannitol, human albumin and sodium 
Zdravilo Betaferon vsebuje manitol, humani albumin in natrij Zdravilo Betaferon vsebuje kot pomožni snovi:
Lymphadenopathy 
limfadenopatija
7 - Remove the blister pack from the vial adapter, holding the blister edges. 
7 - Pretisni omot primite za robove in ga odstranite iz adapterja za vialo.
Each triple pack contains 3 vials with powder, 3 pre-filled syringes with solvent, 3 vial adapters with pre-attached needle and 6 alcohol wipes for skin and vial cleaning. 
3 adapterji za viale z iglami in 6 alkoholnih blazinic za čiščenje kože in vial.
Malaise * × Laboratory abnormality 
× nenormalen izvid laboratorijske preiskave
Musculoskeletal and connective tissue disorders Hypertonia° 
Bolezni mišičnoskeletnega sistema in vezivnega tkiva artralgija eritematozni lupus, povzročen z zdravili
BATCH NUMBER Lot 
Log-rank test
PHARMACEUTICAL FORM AND CONTENTS Titration pack comprising 4 triple packs, each containing: 
Sestavljen je iz 4 tridelnih pakiranj, vsako vsebuje:
Rare ( ≥ 1/10,000 to 
(≥ 1/10.000 do neznana pogostnost 2
NAME OF THE MEDICINAL PRODUCT Betaferon 250 microgram/ml, powder and solvent for solution for injection interferon beta-1b 
Navodilo za uporabo Betaferon 250 mikrogramov/ml prašek in vehikel za raztopino za injiciranje interferon beta-1b
Palpitation * 
BOX')
Urticaria, Pruritus, Alopecia 
Bolezni kože in podkožja urtikarija, pruritus, alopecija sprememba barve kože
This allows any air bubbles to rise to the top of the solution. 
Tako bodo zračni mehurčki na površini raztopine.
Before injection, the Betaferon solution has to be prepared from a vial of Betaferon powder and 1.2 ml of liquid from the pre-filled solvent syringe. 
Pred injiciranjem je treba raztopino zdravila Betaferon pripraviti iz viale s praškom zdravila
NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Betaferon 250 microgram/ml, powder for solution for injection interferon beta-1b Subcutaneous use 
Betaferon 250 mikrogramov/ml prašek za raztopino za injiciranje interferon beta-1b subkutana uporaba
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL OF VIAL (BETAFERON) 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
After reconstitution, 1 ml contains 250 microgram (8.0 million IU) interferon beta-1b*. 
Po rekonstituciji 1 ml vsebuje 250 mikrogramov (8,0 milijonov i.e.) interferona beta-1b*.
It contains syringes with 0.25, 0.5, 0.75 and 1.0 ml markings. 
Vsebuje brizge z oznakami 0,25, 0,5, 0,75 in 1 ml. S trojnim pakiranjem »4« lahko injicirate celotni odmerek 1 ml.
Maximum serum levels of about 40 IU/ml were found 1-8 hours after subcutaneous injection of 500 microgram (16.0 million IU) interferon beta-1b. 
8 ur po subkutani injekciji 500 mikrogramov (16 milijonov i.e.) interferona beta-1b.
Hyperthyroidism, Thyroid disorders 
Bolezni endokrinega sistema hipotiroidizem hipertiroidizem, motnje v delovanju ščitnice
PART III: BETAFERON MEDICATION RECORD 
DEL III: KARTICA O UPORABI ZDRAVILA BETAFERON Navodila za zapisovanje mest injiciranja in datumov
back pain, pain in extremities such as fingers and toes - difficulty urinating (urine retention), protein in the urine (will show up in urine tests), urinary frequency, inability to hold back urination (urinary incontinence), urinary urgency - painful periods (dysmenorrhoea), menstrual disorder, heavy uterine bleeding (metrorrhagia) 
- zastoj seča (retencija urina), beljakovine v seču (pokažejo urinske preiskave), pogosto mokrenje, nezmožnost zadrževanja urina (urinska inkontinenca), nuja na mokrenje - boleče mesečne krvavitve (dismenoreja), menstruacijske motnje, močne krvavitve iz maternice (metroragija), zlasti med mesečnimi krvavitvami, impotenca - reakcije na mestu injiciranja (vključno z rdečico, otekanjem, spremembo barve kože, vnetjem, bolečino, alergijskimi reakcijami (preobčutljivostjo), razkroj kože in poškodbe tkiva (nekroza)
There is no evidence of an effect of Betaferon on the duration of relapses or on symptoms in between relapses, and no significant effect was seen on the progression of the disease in relapsing-remitting multiple sclerosis. 
Pri recidivnoremitentni multipli sklerozi niso opazili nobenega pomembnega vpliva na napredovanje bolezni.
Migraine 
Bolezni živčevja
This should give you an idea of how you can keep track of your injection sites and dates. 
Z njim si pomagajte oblikovati evidenco zapisovanja mest in datumov injiciranja.
(peripheral oedema), lack/loss of strength (asthenia), chills, sweating, malaise 
kopičenje tekočine v rokah, nogah ali obrazu (periferni edem), pomanjkanje/izguba moči
PHARMACEUTICAL FORM Powder and solvent for solution for injection. 
FARMACEVTSKA OBLIKA IN VSEBINA Set za titriranje
Vomiting Λ 
Bolezni prebavil driska zaprtje navzea bruhanje Λ
Caution should be used and close monitoring considered when administering interferon beta to patients with severe renal failure. 
Pri uporabi interferona beta pri bolnikih s hudo ledvično okvaro je potrebna posebna previdnost in pozorno spremljanje bolnikov.
Your doctor also needs to know the following whilst you are using Betaferon: 
Med uporabo zdravila Betaferon morate zdravnika obvestiti tudi:
- kidney problems including scarring (glomerulosclerosis) that may reduce your kidney function, uncommon severe loss of appetite leading to weight loss (anorexia), rare disease of the heart muscle (cardiomyopathy), rare sudden shortness of breath (bronchospasm), rare the liver does not work properly (hepatic injury (including hepatitis), hepatic failure), rare problems with your small blood vessels may develop when using medicines like Betaferon (systemic capillary leak syndrome), frequency unknown rash, redness of the skin in the face, joint pain, fever, weakness and others caused by the medicine (drug-induced lupus erythematosus), frequency unknown severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels that carry blood from the heart to the lungs (pulmonary arterial hypertension), frequency unknown. 
redko - pri uporabi zdravil, kot je zdravilo Betaferon, se lahko pojavijo težave z majhnimi krvnimi žilami (sindrom sistemske kapilarne prepustnosti), pogostnost neznana - izpuščaj, pordelost kože na obrazu, bolečina v sklepih, povišana telesna temperatura, šibkost in drugi, z zdravilom povzročeni neželeni učinki (eritematozni lupus, povzročen z zdravili), pogostnost neznana
Talk to your doctor or nurse about these or any other unusual conditions you may find. 
O vseh takšnih ali drugih neobičajnih spremembah, ki jih najdete, se posvetujte z zdravnikom ali medicinsko sestro.
System Organ Class Adverse Event and Laboratory Abnormalities 
Organski sistem neželeni učinek in nenormalni izvidi laboratorijskih preiskav enkratni dogodek, ki kaže na multiplo sklerozo
4 Class label for interferon products, see below Pulmonary arterial hypertension. 
2 neželeni učinki, o katerih so poročali samo v obdobju trženja 3 označevanje razreda zdravil, ki vsebujejo interferon beta (glejte poglavje 4.4) Velja za skupino zdravil, ki vsebujejo interferone - glejte Pljučna arterijska hipertenzija spodaj.
Withdrawal of Betaferon should be considered if the levels significantly increase or if they are associated with clinical symptoms such as jaundice. 
Če se vrednosti transaminaz pomembno povečajo ali če jih spremljajo klinični simptomi zlatenice, je treba razmisliti o prekinitvi zdravljenja z zdravilom
43% versus placebo HR = 0.57 [0.46, 0.71] p < 0.00001 
RT = 0,57 [0,46; 0,71]
Hepatobiliary disorders Alanine aminotransferase increased (SGPT> 5 times baseline) × Λ * ° 
bolečine v trebuhu ° Bolezni jeter, žolčnika in žolčevodov povečane vrednosti alaninaminotransferaze (SGPT > 5-kratna izhodiščna vrednost) ×
These may be reduced by the use of an auto-injector device. 
Uporaba avtoinjektorja lahko zmanjša simptome.
It can cause disability temporarily, such as difficulty walking. 
Pri zagonu MS (relapsu) se lahko pojavijo spremembe v osrednjem živčevju, ki lahko povzročijo začasno prizadetost, na primer težave pri hoji.
► If you have only one sore injection site (lesion) and the tissue damage (necrosis) is not too extensive you may continue using Betaferon. 
Če vam poči koža zaradi otekanja ali iztekanja tekočine z mesta injiciranja: ► prenehajte z injiciranjem zdravila Betaferon in se posvetujte z zdravnikom, ► če je poškodovano le eno mesto injiciranja (lezija) in poškodbe tkiva (nekroza) niso obsežne, lahko nadaljujete z uporabo zdravila Betaferon, ► če imate več poškodovanih mest injiciranja (multiple lezije), morate prenehati uporabljati zdravilo Betaferon, dokler se koža ne zaceli.
If this is severe a doctor may have to remove foreign matter and dead tissue (debridement) and, less often, skin grafting is required and healing may take up to 6 months. 
bo morda moral zdravnik odstraniti tujke in mrtvo tkivo (debri).
sinusitis, cough increased, shortness of breath (dyspnoea) - diarrhoea, constipation, nausea, vomiting, abdominal pain - rises in the blood levels of liver enzymes (will show up in blood tests) - skin disorder, rash - muscle stiffness (hypertonia), painful muscles (myalgia), muscular weakness (myasthenia), 
- driska, zaprtje, občutek siljenja na bruhanje, bruhanje, bolečine v trebuhu - povečane vrednosti jetrnih encimov v krvi (pokažejo krvne preiskave)
− 3-month pack with 3x15 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or 
vialo s praškom, 1 napolnjeno injekcijsko brizgo z vehiklom, 1 adapter za vialo z iglo, 2 alkoholni blazinici ali - 3-mesečno pakiranje s 3 x 15 posameznimi pakiranji; vsako posamezno pakiranje vsebuje 1 vialo s praškom, 1 napolnjeno injekcijsko brizgo z vehiklom, 1 adapter za vialo z iglo, 2 alkoholni blazinici ali
− 1 pre-filled syringe of solvent for Betaferon (sodium chloride solution 5.4 mg/ml (0.54% w/v)), 
(raztopina natrijevega klorida 5,4 mg/ml (0,54 % m/v)).
Use green triple pack No. 3 for treatment days 13, 15 and 17 Use blue triple pack No. 4 for treatment days 19, 21 and 23 
Uporabite modro tridelno pakiranje 4 za 19., 21. in 23. dan zdravljenja.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF MULTI-MONTH PACK (INCLUDING BLUE BOX) 
ŠKATLA Z VEČMESEČNIMI PAKIRANJI (S PODATKI ZA 'BLUE BOX')
Anaphylactic reactions 
- resne alergijske (anafilaktične) reakcije
Asthenia * 
Bolezni sečil
Contents of the pack and other information 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Betaferon
Then draw up solution as far as the 1.0 ml mark on the syringe: 1.0 ml for the injections at day 19, 21 and 23 of therapy. 
1,0 ml za injiciranje na 19., 21. in 23. dan zdravljenja
Metabolism and nutrition disorders 
Motnje reprodukcije in dojk menoragija
See section 2. 
II, v drugem delu tega navodila).
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 250 mcg (8 m IU) per ml after reconstitution 
250 mikrogramov (8,0 milijonov i.e.)/ml po rekonstituciji
See ‘Warnings and precautions' in section 2 for more information and what to do, if you experience an injection site reaction. 
Če opazite reakcije na mestu injiciranja, glejte poglavje 2, Opozorila in previdnostni ukrepi.
Aspartate aminotransferase increased (SGOT > 5 times baseline) × Λ * ° 
(SGOT > 5-kratna izhodiščna vrednost) ×
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF MULTIPACK (INCLUDING BLUE BOX) 
ŠKATLA Z VEČ PAKIRANJI (S PODATKI ZA 'BLUE BOX')
− Titration pack for dose titration with 4 differently coloured and numbered triple packs: - yellow, with number “1”(treatment days 1, 3 and 5; 0.25-ml syringe marking), - red, with number “2” (treatment days 7, 9 and 11; 0.5-ml syringe marking), - green, with number “3” (treatment days 13, 15 and 17; 0.75-ml syringe marking), - blue, with number “4” (treatment days 19, 21 and 23; 0.25, 0.5, 0.75 and 1-ml syringe marking) 
− modro, označeno s številko »4« (za 19., 21. in 23. dan zdravljenja; oznake 0,25, 0,5, 0,75
Driving and using machines 
POSTOPEK IN POT UPORABE ZDRAVILA
− Pack with 14 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or 
vialo s praškom, 1 napolnjeno injekcijsko brizgo z vehiklom, 1 adapter za vialo z iglo, 2 alkoholni blazinici ali
Posology 
PREDEL
6.1 List of excipients: 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi
STATEMENT OF ACTIVE SUBSTANCE(S) 1 ml contains 250 microgram (8.0 million IU) interferon beta-1b when reconstituted. 
1 ml vsebuje 250 mikrogramov (8,0 milijonov i.e.) interferona beta-1b po rekonstituciji.
Betaferon is indicated for the treatment of 
4.1 Terapevtske indikacije Zdravilo Betaferon je indicirano za zdravljenje
METHOD AND ROUTE OF ADMINISTRATION For subcutaneous injection after reconstitution with 1.2 ml of solvent. 
Po rekonstituciji z 1,2 ml vehikla zdravilo injicirajte subkutano.
1.2 ml sodium chloride solution 5.4 mg/ml 
Vehikel za rekonstitucijo Betaferona 1,2 ml raztopine natrijevega klorida 5,4 mg/ml
Sterile white to off-white powder. 
prašek in vehikel za raztopino za injiciranje sterilen bel do umazano bel prašek
B) Getting ready to inject 
B) Priprava na injiciranje
• 3 pre-filled syringes with solvent for the Betaferon powder (sodium chloride solution 5.4 mg/ml 
1 napolnjena injekcijska brizga z 1,2 ml vehikla: raztopina natrijevega klorida 5,4 mg/ml
If there is no response to treatment after two to three days, doctors should re-evaluate the patient and consider alternative treatments. 
Če po dveh ali treh dneh ni odziva na zdravljenje, mora zdravnik ponovno pregledati bolnika in po presoji uvesti alternativno zdravljenje.
The European Commission granted a marketing authorisation valid throughout the European Union for Altargo to Glaxo Group Ltd on 24 May 2007. 
Evropska komisija je dovoljenje za promet z zdravilom Altargo, veljavno po vsej Evropski uniji, odobrila družbi Glaxo Group Ltd dne 24. maja 2007.
In all five studies, the main measure of effectiveness was the proportion of patients whose infections had cleared up after the end of treatment. 
Glavno merilo učinkovitosti v vseh petih študijah je bil delež bolnikov, pri katerih so okužbe po zaključku zdravljenja izginile.
It is used for short-term treatment of superficial skin infections. 
Uporablja se za kratkotrajno zdravljenje povrhnjih okužb kože.
The effects of Altargo were first tested in experimental models before being studied in humans. 
Učinki zdravila Altargo so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The Committee for Medicinal Products for Human Use (CHMP) decided that Altargo's benefits are greater than its risks for the short term treatment of the following superficial skin infections: 
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Altargo večje od z njim povezanih tveganj pri kratkotrajnem zdravljenju naslednjih povrhnjih okužb kože:
Altargo should only be used on the skin. 
Zdravilo Altargo se uporablja samo na koži.
It is derived from a compound produced by certain types of fungus. 
Je derivat spojine, ki jo proizvajajo določene vrste gliv.
Altargo can be used in patients from the age of nine months, but in patients under 18 years of age, the area to be treated should not be more than 2% of the body's surface. 
Zdravilo Altargo se lahko uporablja pri bolnikih, starejših od devetih mesecev, vendar pa pri bolnikih, mlajših od 18 let, prizadeto območje ne sme presegati 2 % telesne površine.
• infected small lacerations, abrasions or sutured wounds. 
• okužene manjše raztrganine, odrgnine ali zašite rane.
Altargo has been studied in five main studies involving over 3,000 patients aged from 9 months upwards. 
Zdravilo Altargo so preučevali v petih glavnih študijah, ki so zajele več kot 3.000 bolnikov, starih od 9 mesecev dalje.
It works by blocking the bacteria's ribosomes (the parts of the cells where proteins are produced), inhibiting the growth of the bacteria. 
Deluje tako, da zavira ribosome bakterij (dele celice, na katerih poteka sinteza proteinov) in tako preprečuje rast bakterij.
What is the risk associated with Altargo? 
Kakšna tveganja so povezana z zdravilom Altargo?
The data presented were insufficient to support the use of Altargo in the treatment of infected 
Predloženi podatki niso bili zadostni za utemeljitev uporabe zdravila Altargo pri zdravljenju